Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
152 results about "Aminoglycoside Agents" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Streptomycin lacks the common 2-deoxystreptamine moiety (image right, below) present in most other members of this class. Other examples of aminoglycosides include the deoxystreptamine-containing agents kanamycin, tobramycin, gentamicin, and neomycin (see below).
Pulmonary delivery of aminoglycosides
InactiveUS7368102B2Eliminate side effectsReduce in quantityBiocidePowder deliveryRespiratory infectionTopical treatment
Owner:BGP PROD OPERATIONS GMBH +1
Compositions containing pipercillin and tazobactam useful for injection
InactiveUS6900184B2Reduce formationMaintain stabilityBiocidePeptide/protein ingredientsParticulatesDepressant
The invention pertains to pharmaceutical compositions of Zosyn® piperacillin with tazobactam in the presence of a buffer, preferably citrate, a particulate formation inhibitor, preferably EDTA optionally an aminoglycoside which when frozen and thawed or lyophilized and reconstituted reform a solution which has decreased particulate formation.
Owner:MEDICAL SAFETY PROD
Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
InactiveUS20050019926A1High transfection efficiencyAntibacterial agentsPowder deliveryPolymerAminoglycoside Agents
Owner:ARADIGM
Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers
InactiveUS20090156517A1Reduce formationMeet the requirementsAntibacterial agentsBiocideParticulatesAntibiotic Y
A pharmaceutical composition comprising: at least one aminoglycoside antibiotic and (a) at least one ion chelating agent used for inhibiting particulate formation, or (b) at least one buffer, or (c) at least one ion chelating agents and at least one buffer simultaneously. The composition for use in controlling microbial infection can be formulated into a solution, or combined with at least one beta-lactam antibiotic, or combined with at least one of beta-lactam antibiotic and at least one beta-lactamase inhibitor into a solution in a container.
Owner:ZHANG HESHENG
Aminoglycoside treatment for lysosomal storage diseases
ActiveUS20050153906A1Effective treatmentHigh activityBiocideSugar derivativesLysosomal enzyme defectHurler syndrome
The present invention provides a method of treating lysosomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically effective dose of an aminoglycoside. In addition, this method may further comprise treating the individual with enzyme replacement therapy. Furthermore, the present invention provides method of pharmacologically suppressing premature stop mutations in an individual with these lysosomal storage diseases, comprising the step of administering to said individual a pharmacologically effective dose of an aminoglycoside.
Owner:UAB RES FOUND
Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes
InactiveUS20050004052A1High activityOvercome resistanceBiocideSugar derivativesAntibiotic resistanceAntibiotic Y
A novel group of aminoglycosides which share some structural features of currently available aminoglycosides with regard to the backbone, while also having significant structural differences. The similarity enables these aminoglycosides to be highly potent and effective antibiotics, while the significant differences enable these aminoglycosides to reduce or even block antibiotic resistance.
Owner:TECHNION RES & DEV FOUND LTD
Combination of nordihydroguaiaretic acid and an aminoglycoside
InactiveUS20160038438A1Shorten chemotherapy regimeReduce problemsAntibacterial agentsBiocideMicroorganismMicrobiology
The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections.
Owner:HELPERBY THERAPEUTICS LTD
Pharmaceutical compositions and use thereof
InactiveUS20090169635A1Efficient curingIncrease loopAntiinfectivesGranular deliveryAntibacterial activityAntibiotic Y
Colloidal compositions, loaded with non-covalently bonded antibiotics, can be efficiently used for the treatment of severe bacterial pneumonia and other serious lung infections such as tuberculosis. Such formulations, comprised of biodegradable nanoparticles or nanocapsules with incorporated antibiotics, show a significant increase in antibacterial activity, extended and sustained drug release and a decrease in frequency of the drug administration. Antibiotics of various types, such as aminoglycosides, glycopeptides and others can be successfully incorporated into a nanoparticulate colloidal delivery system.
Owner:ALPHARX
Stable pharmaceutical composition comprising beta-lactam antibiotic and ion-chelating agent
InactiveUS20090155387A1Reduce formationAvoid drug resistanceAntibacterial agentsBiocideMedicineAntibiotic Y
A pharmaceutical composition comprising: at least one β-lactam antibiotic and at least one ion-chelating agent; wherein when said pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic.
Owner:ZHANG HESHENG
Derivative of micronomycine and its preparing process and medical application
A series of novel derivatives of micronomycin, its preparing process and the medicines containing them as active component are disclosed. The said derivatives are prepared through alkylating and acylating C1-NH2 of microromycin and chemical reactions. Its advantage is high antibacterial activity.
Owner:四川抗菌素工业研究所有限公司
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Z1, Z2, Z3, Z4, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Nonsense suppressor agents in treatment of cutaneous and gastrointestinal disorders
InactiveUS20050261210A1Suppresses genetic basisAdverse side-effectBiocideCarbohydrate active ingredientsDiseaseSuppressor
The invention features methods of treating a inherited or acquired cutaneous or gastrointestinal (GI) disorder caused by or having a symptom caused by a nonsense mutation by local administration of a nonsense suppressor agent (e.g., an aminoglycoside or nucleic acid encoding a suppressor tRNA) to the skin or intraluminal GI surface so as to provide for phenotypic suppression of the nonsense mutation.
Owner:RGT UNIV OF CALIFORNIA
Aminoglycosides and uses thereof in treating genetic disorders
ActiveUS8895519B2High premature stop-codon mutations read-through activityLow toxicityBiocideMuscular disorderCytotoxicityHigh selectivity
A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I:or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.
Owner:TECHNION RES & DEV FOUND LTD
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Compositions and methods for antibiotic potentiation and drug discovery
The present invention provides methods for identifying target genes whose partial or complete functional inactivation potentiates the activity of an antibiotic agent, e.g., a quinolone antibiotic. The invention further provides methods for identifying agents that modulate expression of target genes or that modulate activity of expression products of target genes. Agents identified according to various methods of the invention potentiate the activity of antibiotics such as quinolones, aminoglycosides, peptide antibiotics and β-lactams. Also provided are agents that suppress and / or retard resistance to antibiotics. The inventive methods provide potentiating agents and compositions comprising potentiating agents and antibiotics. Such agents and compositions can be used for inhibiting growth or survival of a microbial cell or of treating a subject suffering from or susceptible to a microbial infection.
Owner:TRUSTEES OF BOSTON UNIV
Antibacterial aminoglycoside analogs
InactiveUS20110288041A1Stable genetic changeAntibacterial agentsBiocideStereoisomerismStereochemistry
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Antibacterial aminoglycoside analogs
InactiveUS20120122809A1Stable genetic changeAntibacterial agentsBiocideAntibacterial activityStereoisomerism
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Method for specific integration of t7 rna polymerase gene in the chromosome of corynebacterial and the resultant corynebacteria-t7 promoter based shuttle vector system
The present invention relates to method for obtaining optimum expressed proteins in a transformed gram positive bacteria by specific integration of T7 RNA polymerase gene into the chromosome of a gram positive bacteria exhibiting resistance to aminoglycosides, said method comprising:- digesting an E. coli plasmid with a restriction enzyme- digesting the genomic DNA of said gram positive bacteria- ligating the said digested plasmid to the digested genomic DNA of said gram positive bacteria- transforming the said gram positive bacteria protoplasts with the said ligation mixture of step 2 to yield transformed gram positive bacteria (transformants),- screening the said transformants for kanamycin resistance and aminoglycoside sensitivity to ensure that the targetting of the said plasmid vector into the chromosome of the said gram positive bacteria is successful- cloning of the desired gene in the said vector—culturing the transformant in a suitable culture medium- isolating the expressed proteins from the culture medium
Owner:INDIAN INST OF TECH
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Antibacterial aminoglycoside analogs
InactiveUS20120283209A1Stable genetic changeAntibacterial agentsBiocideStereoisomerismStereochemistry
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Antibacterial aminoglycoside analogs
InactiveUS20120283208A1Stable genetic changeAntibacterial agentsBiocideStereoisomerismStereochemistry
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Methods for treating pulmonary non-tuberculous mycobacterial infections
Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.
Owner:INSMED INC
Novel aminoglycosides and uses thereof in the treatment of genetic disorders
ActiveUS20090093418A1Improved termination mutation suppression activityLow toxicityBiocideMuscular disorderChemo enzymaticInosamycins
A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.
Owner:TECHNION RES & DEV FOUND LTD
Aminoglycosides as antibiotics
InactiveUS20050171035A1Effectively kill and effectively inhibit growthEffectively inhibit the growthBiocideSugar derivativesMammalAntibiotic Y
The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminogylcosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).
Owner:WAYNE STATE UNIV
Methods and compositions for the prevention of toxic side effects of aminoglycoside medications
InactiveUS20070082858A1Avoid enteringAvoid absorptionBiocideCarbohydrate active ingredientsSide effectMedicine
Compositions and methods for reducing and / or preventing antibiotic-related damage to cells of the inner ear and the kidney are provided. Such compositions and methods reduce or prevent hearing loss and kidney damage resulting from use of antibiotics, such as aminoglycoside antibiotics. The composition also find use in reducing or preventing inner ear and kidney damage associated with anti-neoplastic agents, other therapeutic drugs, and environmental factors.
Owner:OREGON HEALTH & SCI UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com